In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Abbott , Boehringer Ingelheim co-promote Flomax in US

Executive Summary

Abbott Laboratories licensed US co-promotion rights to Boehringer Ingelheim Pharmaceuticals' Flomax (tamsulosin HCl), a treatment for benign prostatic hyperplasia (BPH). The drug was originally licensed from Yamanouchi in 1994, and BIP launched it in the US in late 1997.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register